(12-04-10)Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial1,2,3

Kerstin Kempf, Christian Herder, Iris Erlund, Hubert Kolb, Stephan Martin, Maren Carstensen, Wolfgang Koenig, Jouko Sundvall, Siamak Bidel, Suvi Kuha and Tuomilehto Jaakko

1 From the Institute of Clinical Diabetology German Diabetes Center Leibniz Center for Diabetes Research at Heinrich Heine University D?sseldorf D?sseldorf Germany (KK CH HK SMMC); the Department of Chronic Disease Prevention National Institute for HealthWelfare Helsinki Finland (IE JS SBJT); the Hagedorn Research Institute Gentofte Denmark (HK); the West-German Centre of DiabetesHealth Sana Clinics D?sseldorf GmbH D?sseldorf Germany (KKSM); the Department of Internal Medicine II? Cardiology University of Ulm Medical Center Ulm Germany (WK); the Hjelt Institute Department of Public Health University of Helsinki Helsinki Finland (SB SKJT);South Ostrobothnia Central Hospital Sein?joki Finland (JT).
2 Supported by the Institute of Scientific Information on Coffee, which is a consortium of major European Coffee Companies. The Institute of Scientific Information had no role in drafting the design, in implementation of the study, in data analysis and interpretation. Additional support was obtained from the German Federal Ministry of Health (Berlin, Germany) and the Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia (D?sseldorf, Germany).
3 Address correspondence to C Herder, Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University D?sseldorf, Auf'm Hennekamp 65, 40225 D?sseldorf, Germany. E-mail: [email protected] .
Background: Coffee consumption is associated with a decreased risk of type 2 diabetes. Suggested mechanisms underlying the association have included attenuation of subclinical inflammation and a reduction in oxidative stress.
Objective: The aim was to investigate the effects of daily coffee consumption on biomarkers of coffee intake, subclinical inflammation, oxidative stress, glucose, and lipid metabolism.
Design: Habitual coffee drinkers (n = 47) refrained for 1 mo from coffee drinking; in the second month they consumed 4 cups of filtered coffee/d and in the third month 8 cups of filtered coffee/d (150 mL/cup). Blood samples were analyzed by gas chromatography?mass spectrometry, bead-based multiplex technology, enzyme-linked immunosorbent assay, or immunonephelometry.
Results: Coffee consumption led to an increase in coffee-derived compounds, mainly serum caffeine, chlorogenic acid, and caffeic acid metabolites. Significant changes were also observed for serum concentrations of interleukin-18, 8-isoprostane, and adiponectin (medians: ?8%, ?16%, and 6%, respectively; consumption of 8 compared with 0 cups coffee/d). Serum concentrations of total cholesterol, HDL cholesterol, and apolipoprotein A-I increased significantly by 12%, 7%, and 4%, respectively, whereas the ratios of LDL to HDL cholesterol and of apolipoprotein B to apolipoprotein A-I decreased significantly by 8% and 9%, respectively (8 compared with 0 cups coffee/d). No changes were seen for markers of glucose metabolism in an oral-glucose-tolerance test.
Conclusions: Coffee consumption appears to have beneficial effects on subclinical inflammation and HDL cholesterol, whereas no changes in glucose metabolism were found in our study. Furthermore, many coffee-derived methylxanthines and caffeic acid metabolites appear to be useful as biomarkers of coffee intake.

Source: Am J Clin Nutr 91: 950-957, 2010

News

---

In evidenza

"L'informazione presente nel sito serve a migliorare, e non a sostituire, il rapporto medico-paziente."

Per coloro che hanno problemi di salute si consiglia di consultare sempre il proprio medico curante.